mGlu1受体激活具有抗精神病样效应且为M4毒蕈碱受体变构调节剂疗效所必需
该研究基于动物模型发现,M4毒蕈碱乙酰胆碱受体激活抑制纹状体多巴胺释放并产生抗精神病样效应,依赖于Gαq/11偶联的mGlu1代谢型谷氨酸受体共激活。mGlu1正向变构调节剂通过内源性大麻素依赖机制发挥强效抗精神病样效应,且不直接抑制多巴胺D1受体信号、不降低动机反应。
要点
- M4抑制纹状体多巴胺释放及抗精神病样效应依赖mGlu1共激活。
- mGlu1正向变构调节剂经内源性大麻素依赖机制发挥抗精神病样效应。
- mGlu1不直接抑制D1受体信号且不降低动机反应,与M4不同。
核心结论
- M4抑制多巴胺释放和抗精神病样效应需要Gαq/11偶联的mGlu1共激活。
- mGlu1正向变构调节剂可能为精神分裂症阳性症状提供新治疗策略。
研究设计与样本
- 研究为动物模型实验,包含电生理与行为学评估,原文未报告具体样本量。
主要发现
- M4抑制纹状体多巴胺释放及抗精神病样效应依赖mGlu1共激活。
- 丘脑-纹状体刺激后增强mGlu1信号足以抑制纹状体多巴胺释放。
- 新型mGlu1正向变构调节剂经内源性大麻素依赖机制发挥强效抗精神病样效应。
- mGlu1不直接抑制多巴胺D1受体信号,也不降低动机反应。
临床怎么用
- 提示高选择性mGlu1正向变构调节剂可能用于精神分裂症阳性症状的治疗。
- GRM1/mGlu1可作为可成药基因组中精神分裂症治疗的潜在靶点。
局限性
- 证据来自动物模型,原文未报告人类临床数据或样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent clinical and preclinical studies suggest that selective activators of the M4 muscarinic acetylcholine receptor have potential as a novel treatment for schizophrenia. M4 activation inhibits striatal dopamine release by mobilizing endocannabinoids, providing a mechanism for local effects on dopamine signaling in the striatum but not in extrastriatal areas. G protein-coupled receptors (GPCRs) typically induce endocannabinoid release through activation of Gαq/11-type G proteins whereas M4 transduction occurs through Gαi/o-type G proteins. We now report that the ability of M4 to inhibit dopamine release and induce antipsychotic-like effects in animal models is dependent on co-activation of the Gαq/11-coupled mGlu1 subtype of metabotropic glutamate (mGlu) receptor. This is especially interesting in light of recent findings that multiple loss of function single nucleotide polymorphisms (SNPs) in the human gene encoding mGlu1 (GRM1) are associated with schizophrenia, and points to GRM1/mGlu1 as a gene within the "druggable genome" that could be targeted for the treatment of schizophrenia. Herein, we report that potentiation of mGlu1 signaling following thalamo-striatal stimulation is sufficient to inhibit striatal dopamine release, and that a novel mGlu1 positive allosteric modulator (PAM) exerts robust antipsychotic-like effects through an endocannabinoid-dependent mechanism. However, unlike M4, mGlu1 does not directly inhibit dopamine D1 receptor signaling and does not reduce motivational responding. Taken together, these findings highlight a novel mechanism of cross talk between mGlu1 and M4 and demonstrate that highly selective mGlu1 PAMs may provide a novel strategy for the treatment of positive symptoms associated with schizophrenia.
引用
- Yohn SE, Foster DJ, Covey DP, et al. Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators. Mol Psychiatry. 2018. PMID: 30116027. doi:10.1038/s41380-018-0206-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。